- CATUG and Crystal Bio have established a partnership with the launch of a joint lab named ‘CATUG-Crystal’ dedicated to providing advanced nucleic acid analytical services.
CATUG, specialises in integrated nucleic acid and drug delivery CRDMO services and Crystal Bio a member of Crystal Pharmatech, have announced a partnership, marking a significant milestone in the field of nucleic acid analysis. The collaboration has led to the launch of the ‘CATUG-Crystal’ joint lab, a dedicated facility for advanced nucleic acid analytical services.
The partnership aims to leverage the unique strengths of both companies, combining CATUG’s expertise in Contract Development and Manufacturing Organisation (CDMO) services with Crystal Bio’s proficiency in nucleic acid analysis. This synergy is expected to drive innovation and excellence in the rapidly evolving field of nucleic acid research and applications.
Dr. Lin Jin, co-founder and CTO of CATUG, also expressed her excitement for this partnership saying, “Crystal Bio is the premier CRO for intricate analytical challenges in CMC, preclinical, and clinical samples for a range of biologic products, including proteins, peptides, antibodies, ADCs, nucleic acids, and more. We are truly thrilled about our partnership with Crystal Bio. This partnership underscores both parties’ shared vision for innovation, quality, and excellence. The launch of CATUG-Crystal joint lab exemplifies our commitment to delivering advanced services that are crucial for various stages of drug development. Together, we are poised to set new standards in the industry, offering cutting-edge analytical solutions tailored to the evolving needs of our clients.”
 Overview of outsourcing trends 
